The Jackson laboratory, as part of the Mycobacteria Research Laboratories and NTM Basic and Translational Research Center, investigates the structure, biosynthesis and transport of cell envelope lipids and (lipo)polysaccharides playing important roles in the physiology and pathogenicity of mycobacteria.
Our laboratory also studies Mycobacterium leprae (the causative agent of leprosy) and emerging non-tuberculous mycobacterial pathogens, the strategies used by these organisms to persist in the environment, and their molecular mechanisms of pathogenicity and resistance to biocides.
Another aspect of our research concerns the development of anti-mycobacterial drugs and the study of their mechanism of action.
People
news and updates view all
Antimalarial drugs show potential for treating chronic lung infections caused by Mycobacterium abscessus, which would improve the quality of life for patients with limited treatment options.
Mary Jackson joined the Conviction et Engagement Avec la Fondation Raoul-Follereau podcast to discuss state of funding for leprosy research.
Using the only approved TB vaccine, Mary Jackson and her research team are developing a novel COVID-19 vaccine candidate.
contact information
Lab: Microbiology rooms B425, B426, B427
Office: Microbiology room B423A
(970) 491-4067
[email protected]